REGN · After hours
$795.33
+0.35% today·exchange $795.33
Regeneron Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes medicines for serious diseases including eye diseases, allergic and inflammatory conditions, cancer, and rare diseases, with key products such as EYLEA, Dupixent, and Libtayo.
Sanofi's New Drugs Poised to Drive Growth Beyond Dupixent
Zacks · 10h ago
Regeneron to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on October 30, 2026
GlobeNewswire · 1d ago
Regeneron Approaching Incremental Catalysts Like Upcoming Olatorepatide Data Readout, RBC Says
MT Newswires · 1d ago
Regeneron (REGN) Stock Still Looks Undervalued After A 40% Run
Simply Wall St. · 1d ago
Regeneron Highlights EYLEA HD Momentum, Dupixent Growth and Pipeline Catalysts
MarketBeat · 2d ago
Vault CRM Extends Market Leadershipas Another Top 20 Biopharma Chooses Veeva
PR Newswire · 3d ago
Headlines from Yahoo Finance. Not investment advice.
